# A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

> **NCT07205796** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shenzhen Shenxin Biotechnology Co., Ltd** · enrollment: 480 (estimated)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** HZ Vaccine (IN001)
- **BIOLOGICAL:** Shingrix

## Key facts

- **NCT ID:** NCT07205796
- **Lead sponsor:** Shenzhen Shenxin Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07205796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07205796, "A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07205796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*